Novo Nordisk rivals see room to compete in $100 bln weight-loss drug market, Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com

Doctors expect patients will need to stay on these drugs long term to maintain their weight loss. Last year, a Novo Nordisk-funded study found patients regained about two-thirds of their lost weight a year after stopping treatment. Smaller biotechs are also vying for a piece of the obesity market and hope large pharmaceutical companies will pay up for partnerships. Over 650 million adults worldwide are obese, more than triple the rate in 1975, and roughly another 1.3 billion are overweight, exacerbating conditions such as heart disease and diabetes., Doctors expect patients will need to stay on these drugs long term to maintain their weight loss. Last year, a Novo Nordisk-funded study found patients regained about two-thirds of their lost weight a year after stopping treatment. Smaller biotechs are also vying for a piece of the obesity market and hope large pharmaceutical companies will pay up for partnerships. Over 650 million adults worldwide are obese, more than triple the rate in 1975, and roughly another 1.3 billion are overweight, exacerbating conditions such as heart disease and diabetes., , Read More